仑伐替尼联合帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌:3期随机CLEAR研究中缓解深度与生存及国际转移性肾细胞癌数据库联盟亚组疗效分析
CLEAR为开放标签、多中心、随机3期试验,比较仑伐替尼联合帕博利珠单抗与舒尼替尼一线治疗晚期透明细胞肾细胞癌。6个月时肿瘤缩小与总生存相关,IMDC中/高危患者中联合组中位无进展生存期22.1个月对比舒尼替尼5.9个月,客观缓解率72.4%对比28.8%。
要点
- 6个月内确认完全缓解或靶病灶缩小>75%的患者24个月总生存概率≥91.7%。
- IMDC中/高危患者中联合组中位无进展生存期22.1个月对比舒尼替尼5.9个月。
- IMDC中/高危患者中联合组客观缓解率72.4%对比舒尼替尼28.8%。
核心结论
- 仑伐替尼联合帕博利珠单抗对比舒尼替尼在晚期肾细胞癌中显示出更优疗效;里程碑分析显示6个月内肿瘤缓解与更长总生存相关。
研究设计与样本
- CLEAR为开放标签、多中心、随机3期试验,一线治疗晚期透明细胞肾细胞癌。
- 患者按1:1:1随机分配至仑伐替尼20 mg口服每日联合帕博利珠单抗200 mg静脉注射每3周一次、仑伐替尼联合依维莫司(未纳入本分析)或舒尼替尼50 mg口服每日用药4周停药2周。
主要发现
- 按肿瘤缩小的里程碑分析显示,仑伐替尼联合帕博利珠单抗组中6个月内确认完全缓解或靶病灶缩小>75%的患者24个月总生存概率≥91.7%。
- 按疾病进展的里程碑分析显示,两组中6个月内无进展的患者死亡概率均更低。
- IMDC风险分类为中/高危的患者中,仑伐替尼联合帕博利珠单抗对比舒尼替尼的中位无进展生存期分别为22.1个月与5.9个月,客观缓解率分别为72.4%与28.8%。
- IMDC风险分类为有利的患者以及有或无靶肾脏病灶的患者中,结果同样支持仑伐替尼联合帕博利珠单抗。
关键数值与推荐
- IMDC中/高危患者中位无进展生存期:仑伐替尼联合帕博利珠单抗组22.1个月对比舒尼替尼组5.9个月。
- IMDC中/高危患者客观缓解率:仑伐替尼联合帕博利珠单抗组72.4%对比舒尼替尼组28.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究结果为探索性分析,未进行把握度计算或分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extent of tumor shrinkage has been deemed a predictor of survival for advanced/metastatic renal cell carcinoma (RCC), a disease with historically poor survival. OBJECTIVE: To perform an exploratory analysis of overall survival (OS) by tumor response by 6 mo, and to assess the efficacy and survival outcomes in specific subgroups. DESIGN, SETTING, AND PARTICIPANTS: CLEAR was an open-label, multicenter, randomized, phase 3 trial of first-line treatment of advanced clear cell RCC. INTERVENTION: Patients were randomized 1:1:1 to lenvatinib 20 mg orally daily with pembrolizumab 200 mg intravenously once every 3 wk, lenvatinib plus everolimus (not included in this analysis), or sunitinib 50 mg orally daily for 4 wk on treatment/2 wk of no treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Landmark analyses were conducted to assess the association of OS with tumor shrinkage and progressive disease status by 6 mo. Progression-free survival, duration of response, and objective response rate (ORR) were analyzed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup and by the presence of target kidney lesions. Efficacy was assessed by an independent review committee as per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS AND LIMITATIONS: Landmark analyses by tumor shrinkage showed that patients enrolled to lenvatinib plus pembrolizumab arm with a confirmed complete response or >75% target-lesion reduction by 6 mo had a 24-mo OS probability of ≥91.7%. A landmark analysis by disease progression showed that patients with no progression by 6 mo had lower probabilities of death in both arms. Patients with an IMDC risk classification of intermediate/poor had longer median progression-free survival (22.1 vs 5.9 mo) and a higher ORR (72.4% vs 28.8%) with lenvatinib plus pembrolizumab versus sunitinib. Similarly, results favored lenvatinib plus pembrolizumab in IMDC-favorable patients and those with/without target kidney lesions. Limitations of the study are that results were exploratory and not powered/stratified. CONCLUSIONS: Lenvatinib plus pembrolizumab showed improved efficacy versus sunitinib for patients with advanced RCC; landmark analyses showed that tumor response by 6 mo correlated with longer OS. PATIENT SUMMARY: In this report of the CLEAR trial, we explored the survival of patients with advanced renal cell carcinoma by assessing how well they initially responded to treatment. We also explored how certain groups of patients responded to treatment overall. Patients were assigned to cycles of either lenvatinib 20 mg daily plus pembrolizumab 200 mg every 3 wk or sunitinib 50 mg daily for 4 wk (followed by a 2-wk break). Patients who either had a "complete response" or had their tumors shrunk by >75% within 6 mo after starting treatment with lenvatinib plus pembrolizumab had better survival than those with less tumor reduction by 6 mo. Additionally, patients who had more severe disease (as per the International Metastatic Renal Cell Carcinoma Database Consortium) at the start of study treatment survived for longer without disease progression with lenvatinib plus pembrolizumab than with sunitinib.
引用
- Grünwald V, Powles T, Kopyltsov E, et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol. 2023. PMID: 36720658. doi:10.1016/j.euo.2023.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。